Objectives

• To make the best-ever malaria vaccine for Plasmodium falciparum;
  • High efficacy
  • Multi-stage
  • Multi-antigen (up to eight!)
  • Deployable
  • Cost-effective

 

We will undertake clinical trials to assess the pre-erythrocytic, blood-stage and mosquito-stage components.

We will use state-of-the art immunomonitoring, key functional assays of vaccine-induced immunogenicity, and pre-erythrocytic and blood-stage parasite challenges to demonstrate vaccine safety, immunogenicity and efficacy.